Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide

Molecular and Cellular Biochemistry

Volumn 331, Issue 1-2, 2009, Pages 207-214

  Yedjou, Clement G ^a   Tchounwou, Paul B ^a  

^a Jackson State University   (United States)

Author keywords

APL; As2O3; c fos; Cyclin A; Cyclin D1; HL 60 cells; P53; RARE

Indexed keywords

ARSENIC TRIOXIDE; CELL PROTEIN; CYCLIN A; CYCLIN D1; PROTEIN C FOS; PROTEIN P53; RETINOIC ACID RESPONSE ELEMENT; UNCLASSIFIED DRUG; CCNA1 PROTEIN, HUMAN; CCND1 PROTEIN, HUMAN; CYCLIN A1; ORGANOARSENIC DERIVATIVE; OXIDE; TUBULIN; TUMOR PROTEIN;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CASE REPORT; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL STRAIN HL 60; CONTROLLED STUDY; DENSITOMETRY; DOSE RESPONSE; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MODULATION; MOLECULAR MECHANICS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; WESTERN BLOTTING; DNA RESPONSIVE ELEMENT; DRUG EFFECT; DRUG SCREENING; GENE EXPRESSION REGULATION; METABOLISM;

ARSENICALS; CYCLIN A1; CYCLIN D1; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HL-60 CELLS; HUMANS; NEOPLASM PROTEINS; OXIDES; PROTO-ONCOGENE PROTEINS C-FOS; RESPONSE ELEMENTS; TUBULIN; TUMOR SUPPRESSOR PROTEIN P53;

EID: 74049160476     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-009-0160-z     Document Type: Article

References (57)

1. Chen GQ, Zhu J, Shi XG, Ni HJ, Zhong HJ, Si GY, Jin XL, Tang W, Li XS, Xong SM, Shen ZX, Sun GL, Ma J, Zhang P, Zhang TD, Gazin C, Naoe T, Chen SJ, Wang ZY, Chen Z (1996) In vitro studies on cellular and molecular mechanisms of arsenic trioxide (AS2O3) in the treatment of acute promyelocytic leukemia: arsenic trioxide induces NB 4 cell apoptosis with down-regulation of bcl-2 expression and modulation of PML-RARα/PML proteins. Blood 88:1052-1061
2. Rego EM, He LZ, Warrell RP Jr, Wang ZG, Pandolfi PP (2000) Retinoic acid (RA) and As2O3 treatment in transgenic models of acute promyelocytic leukemia (APL) unravel the distinct nature of the leukemiamogenic process induced by the PML-RARapha and PLZF-RARalpha oncoproteins. Proc Natl Acad Sci USA 97:10173-10178. doi:10.1073/pnas.180290497
3. Zhu J, Koken MHM, Quignon F, Chelbi-Alix MK, Degos L, Wang ZY, Chen Z, de Thé H (1997) Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci USA 94:3978-3983. doi:10.1073/pnas.94.8.3978 (Pubitemid 27180484)
4. Bode A, Dong Z (2000) Apoptosis induction by arsenic: mechanisms of action and possible clinical applications for treating therapy-resistant cancers. J Drug Resist Updat 3:21-29. doi: 10.1054/drup.2000.0114 (Pubitemid 30246565)
5. Bode AM, Dong Z (2002) The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects. Crit Rev Oncol Hematol 42:5-24. doi:10.1016/S1040-8428(01)00215-3 (Pubitemid 34229146)
6. Wang ZY, Chen Z (2000) Differentiation and apoptosis induction therapy in acute promyelocytic leukemia. Lancet Oncol 1:101-106. doi:10.1016/S1470- 2045(00)00017-6 Review
7. Freshney RI (1983) Culture of animal cells. A manual of basic techniques. Alan Liss Inc (University Library)
8. Yedjou CG, Tchounwou PB (2007) In vitro cytotoxic and genotoxic effects of arsenic trioxide on human leukemia (HL-60) cells using the MTT and alkaline single cell gel electrophoresis (Comet) assays. Mol Cell Biochem 301:123-130. doi:10.1007/s11010-006-9403-4 (Pubitemid 46895152)
9. Bradford MM (1976) A rapid, sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem 72:248-254. doi:10.1016/0003-2697(76)90527-3
10. Powles T, Poele te R, Shamash J, Chaplin T, Propper D, Joel S, Oliver T, Lui MW (2005) Cannnabis-induced cytotoxicity in leukemic cell lines: the role of the cannabinoid receptors and the MAPK pathway. Blood 105(3): 1214-1221. doi:10.1182/blood-2004-03-1182 (Pubitemid 40170896)
11. States JC, Reiners JJ Jr, Pounds JG, Kaplan DJ, Beauerle BD, McNeely SC, Mathieu P, McCabe MJ Jr (2002) Arsenite disrupts mitosis and induces apoptosis in SV40-transformed human skin fibroblasts. Toxicol Appl Pharmacol 180:83-91. doi:10.1006/taap.2002.9376 (Pubitemid 34478550)
12. Huang SC, Lee TC (1998) Arsenite inhibits mitotic division and perturbs spindle dynamics in HeLa S3 cells. Carcinogenesis 19:889-896. doi:10.1093/carcin/19.5.889 (Pubitemid 28376783)
13. McCabe MJ Jr, Singh KP, Reddy SA, Chelladurai B, Pounds JG, Reiners JJ Jr, States JC (2000) Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment and cell cycle phase. J Pharmacol Exp Ther 295:724-733
14. McCollum G, Keng PC, States JC, McCabe MJ Jr (2005) Arsenite delays progression through each cell cycle phase and induces apoptosis following G2/M arrest in U937 myeloid leukemia cells. J Pharmacol Exp Ther 313:877-887. doi:10.1124/jpet.104.080713 (Pubitemid 40604191)
15. Fleckenstein DS, Uphoff CG, Drexler HG, Quentmeier H (2002) Detection of p53 gene mutations by single strand conformational polymorphism (SSCP) in human acute myeloid leukemia-derived cell lines. Leuk Res 26:207-214. doi:10.1016/S0145-2126(01)00107-2 (Pubitemid 34037858)
16. Erster S, Mihara M, Kim RH, Petrenko O, Moll UM (2004) In vivo mitochondrial p53 translocation triggers a rapid first wave of cell death in response to DNA damage that can precede p53 target gene activation. Mol Cell Biol 24:6728-6741. doi:10.1128/MCB.24.15.6728-6741.2004 (Pubitemid 38944352)
17. Bonini P, Cicconi S, Cardinale A, Vitale C, Serafino AL, Ciotti MT, Marlier LN (2004) Oxidative stress induces p53-mediated apoptosis in glia: p53 transcription-independent way to die. J Neurosci Res 75:83-95. doi:10.1002/jnr.10822 (Pubitemid 38049409)
18. Endo H, Kamada H, Nito C, Nishi T, Chan PH (2006) Mitochondrial translocation of p53 mediates release of cytochrome c and hippocampal CA1 neuronal death after transient global cerebral ischemia in rats. J Neurosci 26:7974-7983. doi:10.1523/JNEUROSCI.0897-06.2006 (Pubitemid 44315166)
19. Dumont P, Leu JI, Della Pietra AC III, George DL, Murphy M (2003) The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nat Genet 33:357-365. doi:10.1038/ng1093 (Pubitemid 36278852)
20. Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, Green DR (2004) Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science 303:1010-1014. doi:10.1126/science. 1092734 (Pubitemid 38209704)
21. Arima Y, Nitta M, Kuninaka S, Zhang D, Fujiwara T, Taya Y, Nakao M, Saya H (2005) Transcriptional blockade induces p53-dependent apoptosis associated with translocation of p53 to mitochondria. J Biol Chem 280:19166-19176. doi:10.1074/jbc.M410691200 (Pubitemid 41379623)
22. Patlolla AK, Tchounwou PB (2005) Cytogenetic evaluation of arsenic trioxide in Sprague-Dawley rats. Mutat Res 587:126-133
23. Volgelstein B, Kinzler KW (1992) p53 function and dysfunction. Cell 70:523-526. doi:10.1016/0092-8674(92)90421-8
24. Hollstein M, Rice K, Greenbalt MS, Soussi T, Fuchs R, Sorlie T, Hovig E, Smith-Sorenson B, Montesano R, Harris CC (1994) Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22:3551-3555 (Pubitemid 24299821)
25. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA Jr, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215-221. doi:10.1038/356215a0
26. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 250:1233-1238. doi:10.1126/science.1978757
27. Tchounwou PB, Yedjou CG, Dorsey WC (2003) Arsenic trioxide induced transcriptional activation and expression of stress genes in human liver carcinoma cells (HepG2). Cell Mol BiologyTM 49(7):1071-1079
28. Erster S, Moll UM (2005) Stress-induced p53 runs a transcription- independent death program. Biochem Biophys Res Commun 331:843-850. doi:10.1016/j.bbrc.2005.03.187 (Pubitemid 40615515)
29. Schuler M, Green DR (2005) Transcription, apoptosis and p53: catch-22. Trends Genet 21:182-187. doi:10.1016/j.tig.2005.01.001 (Pubitemid 40269857)
30. Kley N, Chung RY, Fay S, Loeffler JP, Seizinger BR (1992) Repression of the basal c-fos promoter by wild-type p53. Nucleic Acids Res 20:4083-4087. doi:10.1093/nar/20.15.4083
31. Lackinger D, Kaina B (2000) Primary mouse fibroblasts deficient for c-Fos, p53 or for both proteins are hypersensitive to UV light and alkylating agent-induced chromosomal breakage and apoptosis. Mutat Res 457:113-123. doi:10.1016/S0027-5107(00)00133-0
32. Nango R, Chieko T, Tsukamoto I (2003) Jun N-terminal kinase activation and upregulation of p53 and p21 in selenite-induced apoptosis of regenerating liver. Eur J Pharmacol 47:1-8. doi: 10.1016/S0014-2999(03)01764-3 (Pubitemid 36694853)
33. Daum G, Pham J, Deou J (2001) Arsenite inhibits Ras-dependent activation of ERK but activates ERK in the presence of oncogenic Ras in baboon vascular smooth muscle cells. Mol Cell Biochem 217:131-136. doi:10.1023/A:1007276812824 (Pubitemid 32184465)
34. Draetta GF (1994) Mammalian G 1 cyclins. Curr Opin Cell Biol 6:842-846. doi:10.1016/0955-0674(94)90054-X (Pubitemid 24357915)
35. Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclindependent kinases. Genes Dev 9:1149-1163. doi:10.1101/gad.9.10.1149
36. Sgambato A, Han EK, Zhang YJ, Moon RC, Santella RM, Weinstein IB (1995) Deregulated expression of cyclin D1 and other cell cycle-related genes in carcinogen-induced rat mammary tumors. Carcinogenesis 16:2193-2198. doi:10.1093/carcin/16.9.2193
37. Weinstat-Saslow D, Merino MJ, Manrow RE, Bluth RF, Wittenbel KD, Simpson JF (1995) Overexpression of cyclin D mRNA distinguishes invasive and in situ breast carcinomas from nonmalignant lesions. Nat Med 1:1257-1260. doi:10.1038/nm1295-1257
38. Hunter T, Pines J (1994) Cyclins and cancer. II: cyclin D and CDK inhibitors come of age. Cell 79:573-582. doi:10.1016/0092-8674(94)90543-6 (Pubitemid 24363801)
39. Grana X, Reddy EP (1995) Cell cycle control in mammalian cells: role of cyclins, cyclin dependent kinases (CDKs), growth suppressor genes and cyclin-dependent kinase inhibitors (CKIs). Oncogene 11:211-219
40. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV (1994) Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 369:669-671. doi:10.1038/369669a0 (Pubitemid 24199473)
41. Zhang Y, Lin SC (1997) Molecular characterization of the cyclin-dependent kinase inhibitor p27 promoter. Biochim Biophys Acta 1353:307-311
42. Lee RJ, Albanese C, Stenger RJ, Watanabe G, Inghirami G, Haines GK 3rd, Webster M, Muller WJ, Brugge JS, Davis RJ, Pestell RG (1999) 60(v-src) induction of cyclin D1 requires collaborative interactions between the extracellular signal-regulated kinase, p38, and Jun kinase pathways. A role for cAMP response element-binding protein and activating transcription factor-2 in pp60(v-src) signaling in breast cancer cells. J Biol Chem 274:7341-7350. doi:10.1074/jbc.274.11.7341 (Pubitemid 29140552)
43. Ouyang W, Li J, Ma Q, Huang C (2006) Essential roles of PI-3K/Akt/IKK beta}/NF {kappa B pathway in cyclin D1 induction by arsenite in JB6 Cl41 cells. Carcinogenesis 27(4):864-873. doi: 10.1093/carcin/bgi321
44. Lavoie JN, L'Allemain G, Brunet A, Muller R, Pouyssegur J (1996) Cyclin D1 expression is regulated positively by the p42/ p44MAPK and negatively by the p38/HOGMAPK pathway. J Biol Chem 271:20608-20616. doi:10.1074/jbc.271.34.20608 (Pubitemid 26281839)
45. Rodriguez-Puebla ML, Robles AI, Conti CJ (1999) ras activity and cyclin D1 expression: an essential mechanism of mouse skin tumor development. Mol Carcinog 24(1):1-6. doi:10.1002〈(SICI)1098-2744(199901)24:11::AID- MC1〉3.0.CO;2-E
46. Girard F, Strausfeld U, Fernandez A, Lamb NJ (1991) Cyclin A is required for the onset of DNA replication in mammalian fibroblasts. Cell 67:1169-1179. doi:10.1016/0092-8674(91)90293-8
47. Pagano MR, Pepperkok F, Verde W, Ansorge Draetta G (1992) Cyclin A is required at two points in the human cell cycle. EMBO (Eur Mol Biol Organ) J 11:961-971
48. Sherr CJ (1994) G1 phase progression: cycling on cue. Cell 79:551-555. doi:10.1016/0092-8674(94)90540-1 (Pubitemid 24363798)
49. Breitman T, Collins S, Selonick S (1980) Induction of differentiation of the human promyelocytic leukemia cell line (HL-60) by retinoic acid. Proc Natl Acad Sci USA 77:2936. doi:10.1073/pnas.77.5.2936 (Pubitemid 10049852)
50. Breitman T, Collins SJ, Keene B (1981) Terminal differentiation of human promeylocytic cells in culture in response to retinoic acid. Blood 57:1000
51. Evans TRJ, Kaye SB (1999) Retinoids present role and future potential. Br J Cancer 80:1-8. doi:10.1038/sj.bjc.6690312
52. Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schuntz SS, Kramer AM, Lotan R, Peters LL, Dimery TW, Brown BW (1990) Goepfert: prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 323:795-801
53. Lippman SM, Lee JJ, Sabichi AL (1998) Cancer chemoprevention: progress and promise. J Natl Cancer Inst 85:1492-1498
54. Zhang P, Wang SY, Hu XH (1996) Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 17:58-60
55. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qin QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou C, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY (1997) Use of arsenic trioxide in the treatment of acute promyelocytic leukemia (APL): II clinical efficacy and pharmacokinetics in relapsed patients. Blood 89:3354-3360
56. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, deBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr Jr (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339:1341-1348. doi:10.1056/NEJM199811053391901 (Pubitemid 28509343)
57. Chen GQ, Shi XG, Tang W, Xiong SM, Zhu J, Cai X, Han ZG, Ni JH, Shi GY, Jia PM, Liu MM, He KL, Niu C, Ma J, Zhang P, Zhang TD, Paul P, Naoe T, Kitamura K, Miller W, Waxman S, Wang ZY, de The H, Chen SJ, Chen Z (1997) Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): I. As2O3 exerts dose-dependent dual effects on APL cells. Blood 89:3345-3353